Stop the
Waitlists.
End the Waste.

Big Gov Healthcare Failures

Don’t Europe our Healthcare System

Read More

Nearly
2 years

Nearly two years. That is how long a European cancer patient may wait after a drug is approved before it becomes available to them. In many cases, that is the difference between life and death.

597
Days

Data from the European Federation of Pharmaceutical Industries and Associations shows that once a drug is approved in Europe, it now takes an average of 597 days, nearly 20 months, before patients can actually access it. That’s up from 504 days in 2019.

7
MILLION

The National Health Service waiting lists have ballooned to over 7 million cases. Patients with cancer, heart disease, and other serious conditions are routinely delayed for months. Some die before their number is called.

79,130
Names

According to one study from a British think tank, “between September 2024 and August 2025, around 79,130 names were removed from NHS waiting lists across 127 acute trusts because patients had died before reaching the front of the queue. Of those, 28,908 had been waiting longer than the 18-week statutory standard, and 7,737 had waited more than a year.”

With proposals like Medicare for All, and Most Favored Nation drug rationing, we could bring those same bad outcomes to America.

Supporting President Trump's Efforts to Cut Waste, Fraud, and Abuse in the Runaway Tax-Exempt Hospital System

The 340B program, created in 1992, was meant to help safety-net providers stretch scarce resources and serve low-income patients. Over time, however, it has grown into a sprawling, opaque system that too often fails to meet that mission. Today, it is less a targeted lifeline for vulnerable patients than a loosely regulated revenue stream for large hospital systems.

Federal watchdogs have repeatedly warned that oversight is weak and largely dependent on self-policing. Congressional hearings have underscored this concern, with lawmakers noting that “without the data it is hard to know if this program is working as Congress intended.”

Hospitals can purchase drugs at steep discounts and then charge insurers — and sometimes patients — full price, pocketing the difference. Crucially, there is no requirement that these savings be passed on to patients in the form of lower costs or expanded charity care.

Unsurprisingly, evidence suggests that many patients never see the benefit. Researchers have found that 340B hospitals are not necessarily providing more care to low-income populations than their non-340B peers. In some cases, hospitals participating in the program serve communities with fewer low-income patients than comparable nonparticipants.

Meanwhile, the program has been tied to waste, fraud, and abuse concerns. The Government Accountability Office has warned of insufficient oversight and a heightened risk of improper use, particularly as the program has expanded into more complex hospital systems. That expansion has not come with corresponding safeguards.

© Copyright 2026. All Rights Reserved.